Advertisement Inergetics completes final launch preparations for new CBD-Based pain relief supplement - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Inergetics completes final launch preparations for new CBD-Based pain relief supplement

Inergetics, a world-class developer of nutritional and consumer products, announced that it is completing the final development phase for its new Cannabidiol (CBD)-based pain relief product.

Following a meeting with its CBD Initiative Scientific/Medical Advisory Board last November, the company has marked significant progress in readying its first natural CBD-based nutraceutical supplement for introduction to the marketplace.

With the product’s formulation, dosage, naming, brand identity, and regulatory work largely done as well as initial distribution arrangements in place, Inergetics will launch its innovative new pain relief product in the first quarter of 2015.

Inergetics will be holding an exclusive launch event in New York City for the investment community, shareholders and the media to showcase its new CBD-based supplement and its unique properties. The date, time, and location of this event will be announced at a later date.

"We have made tremendous progress over the last few months toward bringing a truly new pain relief solution to the market," said Mike James, CEO of Inergetics.

"We believe the work of the Inergetics team and CBD Initiative Scientific/Advisory Board produced a breakthrough supplement line that marries our ability to develop innovative, natural nutraceuticals with a science-based approach leveraging CBD’s proven benefits to the human body. The product line is intended to improve the lives of people suffering from pain by giving them a natural remedy that is holistic, opiate-free, non-addictive and effective."

"Our unique pain relief brand also benefits from the proven technological excellence and extensive brand support we bring to our entire portfolio of leading supplements," James added.

"We look forward to debuting our product and all its valuable attributes at our upcoming launch event while simultaneously beginning a conversation with physicians, their patients and our stakeholders about the future of pain relief."